{"id":827589,"date":"2025-03-19T11:03:13","date_gmt":"2025-03-19T15:03:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/"},"modified":"2025-03-19T11:03:13","modified_gmt":"2025-03-19T15:03:13","slug":"maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/","title":{"rendered":"MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Nonproprietary drug name approval marks essential step in FDA approval process<\/b><\/li>\n<\/ul>\n<p>CHICAGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<b>MAIA Biotechnology, Inc., (NYSE American: MAIA)<\/b> (\u201cMAIA\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the United States Adopted Names (USAN) Council has approved \u201categanosine\u201d as the nonproprietary (generic) name for its lead molecule THIO, a telomere-targeting anticancer agent in clinical development as a first-in-class treatment for advanced non-small cell lung cancer (NSCLC).\n<\/p>\n<p>\nThe USAN Council is responsible for selecting standardized, informative and unique nonproprietary (generic) drug names. It is made up of experts from the American Medical Association (AMA), the U.S. Pharmacopeial Convention (USP) and the U.S Food and Drug Administration (FDA).\n<\/p>\n<p>\n\u201cThe designation of a new nonproprietary name for THIO is a key step along our development and regulatory pathway as we move forward with Phase 2 and 3 clinical trials,\u201d said Vlad Vitoc, M.D., CEO of MAIA. \u201cWe chose a name inspired by the mechanism of action of our molecule: altering telomeric guanosine of the cancer cells. The generic name ateganosine is a unique and consistent identity that will support clear communication between healthcare providers, patients and researchers.\u201d\n<\/p>\n<p>\nGeneric drug names are used in product information, drug regulation, labelling and prescribing as for promotional materials and scientific literature.\n<\/p>\n<p>\nMAIA will retain the name THIO in its clinical trial designations (THIO-101, THIO-102, THIO-103, THIO-104).\n<\/p>\n<p><b>About Ateganosine<\/b><\/p>\n<p>\nAteganosine (THIO, 6-thio-dG or 6-thio-2\u2019-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2\u2019-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS\/STING) and adaptive (T-cell) immune responses. The sequential treatment with ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type\u2013specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.\n<\/p>\n<p><b>About MAIA Biotechnology, Inc.<\/b><\/p>\n<p>\nMAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.maiabiotech.com&amp;esheet=54225675&amp;newsitemid=20250319291660&amp;lan=en-US&amp;anchor=www.maiabiotech.com&amp;index=1&amp;md5=ebd5fb63ff5fbbb6a6f56e29408fb13d\">www.maiabiotech.com<\/a>.\n<\/p>\n<p><b>Forward Looking Statements<\/b><\/p>\n<p>\nMAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry\u2019s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cfuture,\u201d \u201cpotential,\u201d or \u201ccontinue,\u201d and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, \u201cMAIA,\u201d \u201cCompany,\u201d \u201cwe,\u201d \u201cour,\u201d and \u201cus\u201d refers to MAIA Biotechnology, Inc. and its subsidiaries.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250319291660r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250319291660\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250319291660\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations Contact<br \/>\n<\/b><br \/>+1 (872) 270-3518<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@maiabiotech.com\">ir@maiabiotech.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Illinois<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health FDA Other Science Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250319291660\/en\/1861426\/3\/MAIA_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO Nonproprietary drug name approval marks essential step in FDA approval process CHICAGO&#8211;(BUSINESS WIRE)&#8211;MAIA Biotechnology, Inc., (NYSE American: MAIA) (\u201cMAIA\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the United States Adopted Names (USAN) Council has approved \u201categanosine\u201d as the nonproprietary (generic) name for its lead molecule THIO, a telomere-targeting anticancer agent in clinical development as a first-in-class treatment for advanced non-small cell lung cancer (NSCLC). The USAN Council is responsible for selecting standardized, informative and unique nonproprietary (generic) drug names. It is made up of experts from the American Medical Association (AMA), the U.S. Pharmacopeial Convention (USP) and the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827589","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO Nonproprietary drug name approval marks essential step in FDA approval process CHICAGO&#8211;(BUSINESS WIRE)&#8211;MAIA Biotechnology, Inc., (NYSE American: MAIA) (\u201cMAIA\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the United States Adopted Names (USAN) Council has approved \u201categanosine\u201d as the nonproprietary (generic) name for its lead molecule THIO, a telomere-targeting anticancer agent in clinical development as a first-in-class treatment for advanced non-small cell lung cancer (NSCLC). The USAN Council is responsible for selecting standardized, informative and unique nonproprietary (generic) drug names. It is made up of experts from the American Medical Association (AMA), the U.S. Pharmacopeial Convention (USP) and the &hellip; Continue reading &quot;MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-19T15:03:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250319291660r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO\",\"datePublished\":\"2025-03-19T15:03:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\\\/\"},\"wordCount\":895,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250319291660r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\\\/\",\"name\":\"MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250319291660r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-03-19T15:03:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250319291660r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250319291660r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/","og_locale":"en_US","og_type":"article","og_title":"MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO - Market Newsdesk","og_description":"MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO Nonproprietary drug name approval marks essential step in FDA approval process CHICAGO&#8211;(BUSINESS WIRE)&#8211;MAIA Biotechnology, Inc., (NYSE American: MAIA) (\u201cMAIA\u201d, the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the United States Adopted Names (USAN) Council has approved \u201categanosine\u201d as the nonproprietary (generic) name for its lead molecule THIO, a telomere-targeting anticancer agent in clinical development as a first-in-class treatment for advanced non-small cell lung cancer (NSCLC). The USAN Council is responsible for selecting standardized, informative and unique nonproprietary (generic) drug names. It is made up of experts from the American Medical Association (AMA), the U.S. Pharmacopeial Convention (USP) and the &hellip; Continue reading \"MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-19T15:03:13+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250319291660r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO","datePublished":"2025-03-19T15:03:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/"},"wordCount":895,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250319291660r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/","name":"MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250319291660r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-03-19T15:03:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250319291660r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250319291660r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maia-biotechnology-receives-usan-council-approval-for-ateganosine-as-nonproprietary-name-for-anticancer-agent-thio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MAIA Biotechnology Receives USAN Council Approval for \u201cAteganosine\u201d as Nonproprietary Name for Anticancer Agent THIO"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827589"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827589\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}